Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
{{output}}
Introduction: Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with relapsed/refractory multiple myeloma (RRMM) and ≥1 prior line of therapy (LOT), i... ...
